Healthcare Sales & Marketing Network News: progressive multifocal leukoencephalopathy

Searching News Database: progressive multifocal leukoencephalopathy

HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 4 Apr 2022
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Biopharmaceuticals Neurology

HSMN NewsFeed - 5 Sep 2017
Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Aug 2017
European Commission Grants Approval for Mavenclad (Cladribine Tablets)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals

HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Nov 2013
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions

HSMN NewsFeed - 31 Jan 2013
Pfizer Wins RAPAMUNE(R) Patent Case in Delaware District Court
Biopharmaceuticals Litigation

HSMN NewsFeed - 16 Jan 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jan 2012
Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Diagnostics Neurology Personalized Medicine FDA

HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2009
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Apr 2009
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
Biopharmaceuticals

HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals

HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Feb 2009
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals

HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology

HSMN NewsFeed - 7 Jan 2008
Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 11 Oct 2007
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology

HSMN NewsFeed - 31 Jul 2007
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA

HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 20 Sep 2006
Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML)
Biopharmaceuticals Neurology

HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 Jun 2006
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology

Return to NewsFeed

Additional items found! 17

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 17 additional stories matching:
progressive multifocal leukoencephalopathy
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!